RecallGuide.ca
    Health productsUpdated Jan 3, 2026BEOVUOfficial source

    BEOVU recall in Canada: Risk of eye inflammation and vision problems

    Share:

    In plain language

    This recall involves BEOVU (brolucizumab) injection, a medication used for a specific eye condition. It's being recalled because it may cause an increased risk of intraocular inflammation, retinal vasculitis, and/or retinal vascular occlusion, which can affect vision. Patients should discuss their treatment with their healthcare professional.

    What to do

    • Stop using the product immediately.
    • Consult your healthcare professional for advice.
    • Do not treat with BEOVU at intervals less than 8 weeks beyond the first 3 doses.
    • Discontinue treatment if retinal vasculitis and/or retinal vascular occlusion develop.

    Get alerts for recalls like this

    Get email alerts when new recalls affect products in this category.

    Categories (optional)

    No spam. Unsubscribe anytime. We only email when there's a relevant recall.

    Affected products

    • BEOVU, brolucizumab injection, 6 mg/0.05 mL solution for intravitreal injection

      Model: DIN: 02496976

    Why this matters

    Risk of intraocular inflammation, retinal vasculitis, and/or retinal vascular occlusion

    Do I have this product?

    This recall only applies to specific products. Follow the steps below to check.

    1. 1

      Check the product name

      Make sure your product name matches one of the affected products listed above.

    2. 2

      Check the model number

      Model numbers are typically on the product label or packaging.

      Affected models: DIN: 02496976

    If your product matches one or more of the details above, it may be affected by this recall.

    If your product does not match these details, it is not affected by this recall.

    When in doubt, always check the official notice.

    Want alerts if similar products are recalled in Canada?

    Frequently Asked Questions

    Why was this product recalled?

    Risk of intraocular inflammation, retinal vasculitis, and/or retinal vascular occlusion

    What should consumers do?

    Stop using the product immediately. Consult your healthcare professional for advice. Do not treat with BEOVU at intervals less than 8 weeks beyond the first 3 doses. Discontinue treatment if retinal vasculitis and/or retinal vascular occlusion develop.

    Where was the product sold?

    This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.

    Is there a health risk?

    Yes, there may be a health risk. Risk of intraocular inflammation, retinal vasculitis, and/or retinal vascular occlusion

    When was this product recalled?

    This product was recalled on February 3, 2022.

    Is the BEOVU brand affected by this recall?

    Yes, BEOVU products are affected by this recall. This recall involves BEOVU (brolucizumab) injection, a medication used for a specific eye condition. It's being recalled because it may cause an increased risk of intraocular inflammation, retinal vasculitis, and/or retinal vascular occlusion, which can affect vision. Patients should discuss their treatment with their healthcare professional.